Cargando…
Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model
BACKGROUND: Thiazolidinediones exert anti-inflammatory and anti-oxidative roles and attenuate atherosclerosis by mechanisms partially independent of their metabolizing actions. High doses of angiotensin type 1 receptor (AT(1)R) blocker losartan (LST) seem to promote fat cell formation by preserving...
Autores principales: | Hernandez-Trujillo, Y, Rodriguez-Esparragon, F, Macias-Reyes, A, Caballero-Hidalgo, A, Rodriguez-Perez, Jose C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266907/ https://www.ncbi.nlm.nih.gov/pubmed/18302760 http://dx.doi.org/10.1186/1475-2840-7-3 |
Ejemplares similares
-
Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro
por: Ren, Liqun, et al.
Publicado: (2011) -
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
por: Vitale, Cristiana, et al.
Publicado: (2005) -
Effects of Losartan on expression of connexins at the early stage of atherosclerosis in rabbits
por: Ruan, Li-ming, et al.
Publicado: (2010) -
Effects of rosiglitazone on serum paraoxonase activity
and metabolic parameters in patients with type 2 diabetes
mellitus
por: Atamer, Y., et al.
Publicado: (2013) -
CD36, a scavenger receptor implicated in atherosclerosis
por: Park, Young Mi
Publicado: (2014)